Furthermore, the novel bispecific monoclonal antibody ZGGS15, which competitively inhibits the binding of LAG-3 to MHC class II and the binding of T cell immunoreceptor with immunoglobulin and ITIM domain (TIGIT) to CD155, significantly suppressed tumor growth in melanoma-bearing mice with a weak response to anti-PD-1 treatment [138]. Here, LAG3 is linked to neoplasm.